B.Braun to expand local IV therapy manufacturing facility

Part of what B. Braun is calling the “Solutions for Life” initiative, the investments aim to help prevent IV fluid shortages in the United States.

“IV fluids are a fundamental component of patient care to hydrate patients, administer drugs and replace lost blood volume,” Dr. Maria Angela Karpf, corporate vice president for B. Braun Medical Inc., said in a statement.

“In recent years, the U.S. market has seen destructive weather events and severe influenza seasons contributing to major nationwide IV fluid shortages. These shortages forced health care professionals and facilities to delay patient treatments or use alternate techniques.”

Caroll H. Neubauer, CEO and chairman of B. Braun, announced the Solutions for Lifeinitiative May 14 at a stakeholder briefing and panel discussion in Washington, D.C., which included legislative leaders.

“IV fluid shortages have the potential to cause serious complications for patients across the country, particularly in times of public health emergencies,” said Pennsylvania Republican Sen. Pat Toomey. “B. Braun is making an important investment to address this concern by expanding production capacity and improving the ability to deliver IV fluids when and where they are needed.”

B. Braun Medical Inc. is part of the B. Braun Group of Companies, which includes B. Braun Interventional Systems, Aesculap and CAPS.

Globally, the B. Braun Group of Companies employs more than 63,000 employees in 64 countries.

LVB Business Events

Business Growth Symposium

Thursday, June 13, 2019
Business Growth Symposium

2019 Health Care Symposium

Thursday, August 01, 2019
2019 Health Care Symposium

2019 Healthcare Heroes Awards

Thursday, August 29, 2019
2019 Healthcare Heroes Awards

2019 CFO of the Year Awards

Wednesday, September 11, 2019
2019 CFO of the Year Awards